NeuroPace Inc (NASDAQ: NPCE) has experienced a rise in its stock price by 2.75 compared to its previous closing price of 7.28. However, the company has seen a gain of 12.48% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-13 that NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jeremy Feffer – Managing Director, LifeSci Advisors Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Vikramjeet Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Mike Kratky – Leerink Partners Frank Takkinen – Lake Street Capital Markets Robert Marcus – JP Morgan Michael Polark – Wolfe Research Operator Good afternoon and welcome to NeuroPace’s Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Is It Worth Investing in NeuroPace Inc (NASDAQ: NPCE) Right Now?
Company’s 36-month beta value is 1.82.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NPCE is 13.99M, and currently, short sellers hold a 3.42% ratio of that floaft. The average trading volume of NPCE on August 14, 2024 was 100.87K shares.
NPCE’s Market Performance
NPCE’s stock has seen a 12.48% increase for the week, with a -6.73% drop in the past month and a -12.10% fall in the past quarter. The volatility ratio for the week is 6.97%, and the volatility levels for the past 30 days are at 8.64% for NeuroPace Inc The simple moving average for the past 20 days is 0.14% for NPCE’s stock, with a -29.14% simple moving average for the past 200 days.
Analysts’ Opinion of NPCE
Many brokerage firms have already submitted their reports for NPCE stocks, with Wells Fargo repeating the rating for NPCE by listing it as a “Overweight.” The predicted price for NPCE in the upcoming period, according to Wells Fargo is $20 based on the research report published on March 14, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see NPCE reach a price target of $22. The rating they have provided for NPCE stocks is “Outperform” according to the report published on January 30th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to NPCE, setting the target price at $11 in the report published on November 10th of the previous year.
NPCE Trading at 5.12% from the 50-Day Moving Average
After a stumble in the market that brought NPCE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.79% of loss for the given period.
Volatility was left at 8.64%, however, over the last 30 days, the volatility rate increased by 6.97%, as shares sank -3.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.69% upper at present.
During the last 5 trading sessions, NPCE rose by +9.47%, which changed the moving average for the period of 200-days by +16.85% in comparison to the 20-day moving average, which settled at $7.46. In addition, NeuroPace Inc saw -27.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NPCE starting from ORBIMED ADVISORS LLC, who sale 15,690 shares at the price of $14.02 back on May 01 ’24. After this action, ORBIMED ADVISORS LLC now owns 3,419,851 shares of NeuroPace Inc, valued at $219,974 using the latest closing price.
ORBIMED ADVISORS LLC, the 10% Owner of NeuroPace Inc, sale 8,842 shares at $14.01 during a trade that took place back on May 02 ’24, which means that ORBIMED ADVISORS LLC is holding 3,411,009 shares at $123,876 based on the most recent closing price.
Stock Fundamentals for NPCE
Current profitability levels for the company are sitting at:
- -0.38 for the present operating margin
- 0.74 for the gross margin
The net margin for NeuroPace Inc stands at -0.46. The total capital return value is set at -0.31. Equity return is now at value -192.19, with -30.41 for asset returns.
Based on NeuroPace Inc (NPCE), the company’s capital structure generated 0.81 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at 4.16. The interest coverage ratio of the stock is -3.0.
Currently, EBITDA for the company is -25.57 million with net debt to EBITDA at -2.61. When we switch over and look at the enterprise to sales, we see a ratio of 3.89. The receivables turnover for the company is 5.94for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.37.
Conclusion
In a nutshell, NeuroPace Inc (NPCE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
